Berenberg raises AbbVie PT on higher immunology drug sales

** Berenberg raises PT on drugmaker AbbVie ABBV.N to $195 from $165, citing higher immunology drug sales

** New PT is a 8.7% downside to stock's last close

** Brokerage says AbbVie knows the autoimmune market well

** Says co reduced exposure to antirheumatic drug Humira and bolstered cash flows through acquisition of Allergan

** "We now forecast $36 bln peak sales for Skyrizi to give an NPV of $60/share (32% of total)," says brokerage

** Skyrizi is used to treat psoriasis and other inflammatory conditions

** Nineteen of 27 brokerages rate stock "buy" or higher, and 8 "hold; median PT is $215 - data compiled by LSEG

** ABBV up 20.2% YTD as of last close; up ~15% in 2024